NDAORALSOLUTIONPriority Review
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
NORVIR (ritonavir) by AbbVie is [see microbiology ( ) ] . First approved in 1996.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral protease inhibitor solution approved in 1996 for HIV treatment. It works by inhibiting HIV protease, preventing viral replication and reducing viral load in infected patients. Ritonavir is now primarily used as a pharmacokinetic booster in combination antiretroviral regimens rather than as a standalone therapeutic agent.
$0.753MPart D
LOE ApproachingDeclining
Declining revenue and minimal Part D claims indicate a mature, contracted franchise with reduced commercial team investment and limited growth opportunities.
Mechanism of Action
[see Microbiology ( ) ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
26 enrolled
HIV Infections
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
100 enrolled
HIV Infections
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
18 enrolled
HIV Infections
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
1,300 enrolled
HIV Infections
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
29 enrolled
HIV Infections
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.